Evidence map›Paper›PMID 35605522›Full record

SynthesisEuropean journal of cancer (Oxford, England : 1990)2022

Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.

Jaffer A Ajani, Lisa Leung, Prianka Singh, Murat Kurt, Inkyu Kim, Mir-Masoud Pourrahmat, Steve Kanters

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 8 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 8 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jaffer A AjaniUniversity of Texas M.D. Anderson Cancer Center, Houston, USA.
Lisa LeungEvidinno Outcomes Research Inc, Vancouver, BC, Canada. Electronic address: lleung@evidinno.com.
Prianka SinghBristol Myers Squibb, Lawrenceville, NJ, USA.
Murat KurtBristol Myers Squibb, Lawrenceville, NJ, USA.
Inkyu KimBristol Myers Squibb, Lawrenceville, NJ, USA.
Mir-Masoud PourrahmatEvidinno Outcomes Research Inc, Vancouver, BC, Canada.
Steve KantersEvidinno Outcomes Research Inc, Vancouver, BC, Canada.
Bristol-Myers Squibb (United States) · USBlinn College · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate disease-free survival (DFS) as a surrogate endpoint for overall survival (OS) using aggregate-level data from resectable esophageal or gastroesophageal junction cancer (EC/GEJC) trials assessing therapies in (neo)adjuvant and perioperative settings.

methodsA systematic literature review was conducted to identify trials reporting OS and DFS, or compatible progression-free survival (PFS). Bivariate random-effects meta-analysis was used to estimate correlation between the treatment effects on DFS/PFS and OS, and weighted linear regression models assuming trial sample sizes as weights were used to estimate surrogacy equations. The primary analysis consisted of trials across all treatment settings, and secondary analysis consisted of trials only in the adjuvant setting. Leave-one-out cross-validation (LOOCV) was performed to measure the stability and predictive accuracy of the surrogacy equations while surrogate threshold effects (STE)-the minimum treatment effect on DFS/PFS that would translate into a positive OS benefit-were derived to measure their usefulness.

resultsThe primary analysis included 26 trials. The estimated correlation coefficient between the hazard ratio (HR) of DFS/PFS (HR

conclusionsOur meta-analysis suggests that HR

Indexed as

Esophageal NeoplasmsNeoplasm Recurrence, LocalAdultBiomarkersDisease-Free SurvivalEsophagogastric JunctionHumansProgression-Free SurvivalBiomarkersDisease-free survivalEsophageal cancerGastroesophageal junction cancerMeta-analysisOverall survivalSurrogacy

Identifiers

PMID35605522
OpenAlexW4280552980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.